The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis
Open accessAbstract
Aberrant hepatocyte Notch activation is required for development of NASH-associated fibrosis, and Notch inhibition ameliorates obesity-induced liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In parallel, cholesterol and other mediators contribute to changes in the transcriptional programmes in steatotic hepatocytes, leading to an upregulation of developmental pathways that are often seen in bipotential progenitor cells or ductular cells, such as Notch and TAZ, which can directly activate pro-fibrotic cell-cell communication between hepatocytes and neighbouring cells.[28], [29], [30]”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [29]
In the citing paper
“osteopontin, which is induced by Notch and TAZ signalling129”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [129]
In the citing paper
“Blocking notch signaling in MASH, both genetically and pharmacologically, can attenuate MASH-associated liver fibrosis (114).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [114]
In the citing paper
“Notch signaling has been identified as an important driver of HSC activation in fibrosis in general (114, 153).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [114]
In the citing paper
“In hepatocytes, activation of TLR4 increases the expression of jagged 1 (JAG1), a well-established notch receptor 1 (NOTCH1) ligand, which leads to SRY-box transcription factor 9 (SOX9)-dependent transcription and secretion of SPP1, stimulating HSC activation (114).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Prevalence of Obesity Among Adults and Youth: United States, 2015-2016.
Hales, C. M., Carroll, M. D., Fryar, C. D., & Ogden, C. L. (2017) · PubMed · Cited by 3,889
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Nonalcoholic Fatty Liver Disease
Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,320
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Obesity and Diabetes in the Developing World — A Growing Challenge
Hossain, P., Kawar, B., & El Nahas, M. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068177 · Cited by 2,200
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
van Es, J. H., van Gijn, M. E., Riccio, O., van den Born, M., Vooijs, M., Begthel, H., Cozijnsen, M., Robine, S., Winton, D. J., Radtke, F., et al. (2005) · Nature · doi:10.1038/nature03659 · Cited by 1,587
Mederacke, I., Hsu, C. C., Troeger, J. S., Huebener, P., Mu, X., Dapito, D. H., Pradere, J.-P., & Schwabe, R. F. (2013) · Nature Communications · doi:10.1038/ncomms3823 · Cited by 1,443
Self-citationYounossi, Z. M., Stepanova, M., Afendy, M., Fang, Y. H., Younossi, Y., Mir, H., & Srishord, M. K. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.020 · Cited by 1,072
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
Geary, R. S., Norris, D. A., Yu, R. Z., & Bennett, C. F. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.008 · Cited by 866
Hippo Pathway Activity Influences Liver Cell Fate
Yimlamai, D., Christodoulou, C., Galli, G. G., Yanger, K., Pepe-Mooney, B., Gurung, B., Shrestha, K., Cahan, P., Stanger, B. Z., & Camargo, F. D. (2014) · Cell · doi:10.1016/j.cell.2014.03.060 · Cited by 857
Knocking down disease: a progress report on siRNA therapeutics
Wittrup, A., & Lieberman, J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3978 · Cited by 827
Notch signaling controls multiple steps of pancreatic differentiation
Murtaugh, L. C., Stanger, B. Z., Kwan, K. M., & Melton, D. A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2436557100 · Cited by 782
Kim, D., Kim, R. W., Kim, H. J., & Therneau, T. M. (2013) · Hepatology · doi:10.1002/hep.26156 · Cited by 772
The Epidemiology of Nonalcoholic Fatty Liver Disease: A Global Perspective
Lazo, M., & Clark, J. M. (2008) · Seminars in Liver Disease · doi:10.1055/s-0028-1091978 · Cited by 744
Mancina, R. M., Dongiovanni, P., Petta, S., Pingitore, P., Meroni, M., Rametta, R., Borén, J., Montalcini, T., Pujia, A., Wiklund, O., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.032 · Cited by 676
Self-citationNonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044224 · Cited by 641
Pradere, J.-P., Kluwe, J., De Minicis, S., Jiao, J.-J., Gwak, G.-Y., Dapito, D. H., Jang, M.-K., Guenther, N. D., Mederacke, I., Friedman, R., et al. (2013) · Hepatology · doi:10.1002/hep.26429 · Cited by 613
Self-citationNotch Signaling in Development and Cancer
Bolós, V., Grego‐Bessa, J., & de la Pompa, J. L. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0046 · Cited by 553
Pathogenesis of Nonalcoholic Steatohepatitis
Machado, M. V., & Diehl, A. M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.066 · Cited by 549
Self-citationHigh-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers
Mederacke, I., Dapito, D. H., Affò, S., Uchinami, H., & Schwabe, R. F. (2015) · Nature Protocols · doi:10.1038/nprot.2015.017 · Cited by 548
Self-citationAntisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Self-citationAnimal models of nonalcoholic fatty liver disease
Hebbard, L., & George, J. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.191 · Cited by 509
Targeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
Self-citationHybrid Periportal Hepatocytes Regenerate the Injured Liver without Giving Rise to Cancer
Font-Burgada, J., Shalapour, S., Ramaswamy, S., Hsueh, B., Rossell, D., Umemura, A., Taniguchi, K., Nakagawa, H., Valasek, M. A., Ye, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.026 · Cited by 486
Robust cellular reprogramming occurs spontaneously during liver regeneration
Yanger, K., Zong, Y., Maggs, L. R., Shapira, S. N., Maddipati, R., Aiello, N. M., Thung, S. N., Wells, R. G., Greenbaum, L. E., & Stanger, B. Z. (2013) · Genes & Development · doi:10.1101/gad.207803.112 · Cited by 484
Pathology of nonalcoholic fatty liver disease
Brunt, E. M. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.21 · Cited by 484
Richardson, M. M., Jonsson, J. R., Powell, E. E., Brunt, E. M., Neuschwander–Tetri, B. A., Bhathal, P. S., Dixon, J. B., Weltman, M. D., Tilg, H., Moschen, A. R., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.012 · Cited by 482
Pathology of Nonalcoholic Fatty Liver Disease
Yeh, M. M., & Brunt, E. M. (2007) · American Journal of Clinical Pathology · doi:10.1309/rtpm1py6ygbl2g2r · Cited by 469
Rinella, M. E., & Green, R. M. (2003) · Journal of Hepatology · doi:10.1016/j.jhep.2003.09.020 · Cited by 462
Selection and evaluation of clinically relevant AAV variants in a xenograft liver model
Lisowski, L., Dane, A. P., Chu, K., Zhang, Y., Cunningham, S. C., Wilson, E. M., Nygaard, S., Grompe, M., Alexander, I. E., & Kay, M. A. (2014) · Nature · doi:10.1038/nature12875 · Cited by 450
Notch signaling controls liver development by regulating biliary differentiation
Zong, Y., Panikkar, A., Xu, J., Antoniou, A., Raynaud, P., Lemaigre, F. P., & Stanger, B. Z. (2009) · Development · doi:10.1242/dev.029140 · Cited by 443
Targeting Notch signaling pathway in cancer: Clinical development advances and challenges
Takebe, N., Nguyen, D., & Yang, S. X. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.005 · Cited by 436
Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis
Wang, X., Zheng, Z., Caviglia, J. M., Corey, K. E., Herfel, T. M., Cai, B., Masia, R., Chung, R. T., Lefkowitch, J. H., Schwabe, R. F., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.016 · Cited by 413
Self-citationGraham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300367 · Cited by 377
Self-citationHepatic Stellate Cell Behavior during Resolution of Liver Injury
Iredale, J. P. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-17557 · Cited by 333
Links Between Hepatic Fibrosis, Ductular Reaction, and Progenitor Cell Expansion
Williams, M. J., Clouston, A. D., & Forbes, S. J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.11.034 · Cited by 308
Gender and racial differences in nonalcoholic fatty liver disease
Pan, J. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i5.274 · Cited by 307
Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics
Lorenzer, C., Dirin, M., Winkler, A.-M., Baumann, V., & Winkler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.003 · Cited by 284 · cited 1×
“However, because liver-targeted Notch antagonism may be fraught with side effects including disruption of hepatic vascular integrity (62), N-acetylgalactosamine–modified siRNA (63, 64) or nanoparticle strategies (65) retain great potential to address the inappropriate Fig.”
Notch signaling is an important regulator of type 2 immunity
Tu, L., Fang, T., Artis, D., Shestova, O. E., Pross, S. E., Maillard, I. P., & Pear, W. S. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050923 · Cited by 283
Notch inhibitors for cancer treatment
Espinoza, I. C., & Miele, L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.02.003 · Cited by 276
Syn, W.-K., Choi, S. S., Liaskou, E., Karaca, G. F., Agboola, K. M., Oo, Y. H., Mi, Z., Pereira, T. A., Zdanowicz, M., Malladi, P., et al. (2011) · Hepatology · doi:10.1002/hep.23998 · Cited by 275
Self-citationInhibition of Notch signaling promotes browning of white adipose tissue and ameliorates obesity
Bi, P., Shan, T., Liu, W., Yue, F., Yang, X., Liang, X.-R., Wang, J., Li, J., Carlesso, N., Liu, X., et al. (2014) · Nature Medicine · doi:10.1038/nm.3615 · Cited by 271
Urtasun, R., Lopategi, A., George, J., Leung, T. M., Lu, Y., Wang, X., Ge, X., Fiel, M. I., & Nieto, N. (2011) · Hepatology · doi:10.1002/hep.24701 · Cited by 257
Self-citationHepatocellular carcinoma originates from hepatocytes and not from the progenitor/biliary compartment
Mu, X., Español‐Suñer, R., Mederacke, I., Affò, S., Manco, R., Sempoux, C. L., Lemaigre, F. P., Adili, A., Yuan, D., Weber, A., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77995 · Cited by 224
Self-citationInhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner
Pajvani, U. B., Shawber, C. J., Samuel, V. T., Birkenfeld, A. L., Shulman, G. I., Kitajewski, J., & Accili, D. (2011) · Nature Medicine · doi:10.1038/nm.2378 · Cited by 193
Self-citationSahai, A., Malladi, P., Melin-Aldana, H., Green, R. M., & Whitington, P. F. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00002.2004 · Cited by 181
Endocytic regulation of Notch signaling
Fortini, M., & Bilder, D. H. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.04.005 · Cited by 176
Shen, Q., & Christakos, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504166200 · Cited by 173
Pajvani, U. B., Qiang, L., Kangsamaksin, T., Kitajewski, J., Ginsberg, H. N., & Accili, D. (2013) · Nature Medicine · doi:10.1038/nm.3259 · Cited by 172
Self-citationBiomimetic strategies for targeted nanoparticle delivery
Dehaini, D., Fang, R. H., & Zhang, L. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10004 · Cited by 172
Chalasani, N., Sanyal, A. J., Kowdley, K. V., Robuck, P. R., Hoofnagle, J. H., Kleiner, D. E., Ünalp, A., & Tonascia, J. A. (2008) · Contemporary Clinical Trials · doi:10.1016/j.cct.2008.09.003 · Cited by 166
Suzuki, A., & Diehl, A. M. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-051215-031109 · Cited by 163
Self-citationNeural crest expression of Cre recombinase directed by the proximal Pax3 promoter in transgenic mice
Li, J., Chen, F., & Epstein, J. A. (2000) · genesis · doi:10.1002/(sici)1526-968x(200002)26:2 · Cited by 158
Lineage fate of ductular reactions in liver injury and carcinogenesis
Jörs, S., Jeliazkova, P., Ringelhan, M., Thalhammer, J., Dürl, S., Ferrer, J., Sander, M., Heikenwalder, M., Schmid, R. M., Siveke, J. T., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78585 · Cited by 149
Inhibition of Notch Signaling by a γ-Secretase Inhibitor Attenuates Hepatic Fibrosis in Rats
Chen, Y., Zheng, S., Qi, D., Zheng, S., Guo, J., Zhang, S., & Weng, Z. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046512 · Cited by 140
Machado, M. V., Michelotti, G. A., Pereira, T. A., Xie, G., Premont, R., Cortez-Pinto, H., & Diehl, A. M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.031 · Cited by 135
Self-citationHepatic Notch Signaling Correlates With Insulin Resistance and Nonalcoholic Fatty Liver Disease
Valenti, L. V. C., Mendoza, R. M., Rametta, R., Maggioni, M., Kitajewski, C., Shawber, C. J., & Pajvani, U. B. (2013) · Diabetes · doi:10.2337/db13-0769 · Cited by 113
Self-citationOsteopontin induces ductular reaction contributing to liver fibrosis
Wang, X., Lopategi, A., Ge, X., Lu, Y., Kitamura, N., Urtasun, R., Leung, T.-M., Fiel, M. I., & Nieto, N. (2014) · Gut · doi:10.1136/gutjnl-2013-306373 · Cited by 108
Self-citationBansal, R., van Baarlen, J., Storm, G., & Prakash, J. (2015) · Scientific Reports · doi:10.1038/srep18272 · Cited by 107
Osteopontin neutralisation abrogates the liver progenitor cell response and fibrogenesis in mice
Coombes, J. D., Swiderska‐Syn, M., Dollé, L., Reid, D. T., Eksteen, B., Claridge, L. C., Briones-Orta, M. A., Shetty, S., Oo, Y. H., Riva, A., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-306484 · Cited by 97
Self-citationTabuchi, K., Chen, G., Südhof, T. C., & Shen, J. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1320-09.2009 · Cited by 96
A bright single-cell resolution live imaging reporter of Notch signaling in the mouse
Nowotschin, S., Xenopoulos, P., Schrode, N., & Hadjantonakis, A. (2013) · BMC Developmental Biology · doi:10.1186/1471-213x-13-15 · Cited by 90
mTORC1-independent Raptor prevents hepatic steatosis by stabilizing PHLPP2
Kim, K., Qiang, L., Hayden, M. S., Sparling, D. P., Purcell, N. H., & Pajvani, U. B. (2016) · Nature Communications · doi:10.1038/ncomms10255 · Cited by 70
Self-citationMolecular mechanisms of liver and bile duct development
Zong, Y., & Stanger, B. Z. (2012) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.47 · Cited by 65
Miller, C. M., Tanowitz, M., Donner, A. J., Prakash, T. P., Swayze, E. E., Harris, E. N., & Seth, P. P. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0709 · Cited by 65
Endothelial notch signaling is essential to prevent hepatic vascular malformations in mice
Cuervo, H., Nielsen, C. M., Simonetto, D. A., Ferrell, L. D., Shah, V. H., & Wang, R. A. (2016) · Hepatology · doi:10.1002/hep.28713 · Cited by 59
He, F., Guo, F., Li, Z., Yu, H., Ma, P., Zhao, J., Feng, L., Li, W., Liu, X., Qin, H., et al. (2015) · Hepatology · doi:10.1002/hep.27394 · Cited by 54
Nicastrin: Gatekeeper of the γ-Secretase Complex
Strooper, B. D. (2005) · Cell · doi:10.1016/j.cell.2005.07.021 · Cited by 49
Pharmacotherapy for Nonalcoholic Fatty Liver Disease
Gawrieh, S., & Chalasani, N. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1562951 · Cited by 35
Notch signaling and progenitor/ductular reaction in steatohepatitis
Morell, C. M., Fiorotto, R., Meroni, M., Raizner, A., Torsello, B., Cadamuro, M., Spagnuolo, G., Kaffe, E., Sutti, S., Albano, E., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187384 · Cited by 32
Self-citationγ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor
Kim, K., Goldberg, I. J., Graham, M. J., Sundaram, M., Bertaggia, E., Lee, S. X., Qiang, L., Haeusler, R. A., Metzger, D., Chambon, P., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.010 · Cited by 26
Self-citationSparling, D. P., Yu, J., Kim, K., Zhu, C., Brachs, S., Birkenfeld, A. L., & Pajvani, U. B. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.11.006 · Cited by 24
Self-citationCaregiving for Older Adults with Obesity in the United States
Ankuda, C. K., Harris, J. A., Ornstein, K. A., Levine, D. A., Langa, K. M., & Kelley, A. S. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14918 · Cited by 7
Flagged first, then by citations
Cited by
Sorted by citations
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Notch signaling pathway: architecture, disease, and therapeutics
Zhou, B., Lin, W., Long, Y., Yang, Y., Zhang, H., Wu, K., & Chu, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00934-y · Cited by 1,216
Senolytic CAR T cells reverse senescence-associated pathologies
Amor, C., Feucht, J., Leibold, J., Ho, Y.-J., Zhu, C., Alonso-Curbelo, D., Mansilla-Soto, J., Boyer, J. A., Li, X., Giavridis, T., et al. (2020) · Nature · doi:10.1038/s41586-020-2403-9 · Cited by 1,098
Self-citationMechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis
Schwabe, R. F., Tabas, I., & Pajvani, U. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.311 · Cited by 671
Self-citation
Metadata
- Authors
- Zhu, C., Kim, K., Wang, X., Bartolome, A., Salomao, M., Dongiovanni, P., Meroni, M., Graham, M. J., Yates, K. P., Diehl, A. M., Schwabe, R. F., Tabas, I., Valenti, L., Lavine, J. E., & Pajvani, U. B.
- Affiliations
- Columbia University (US)
- Department of Medicine, Columbia University, New York, NY 10032, USA.
- Mayo Clinic (US)
- University of Milan (IT)
- Ionis Pharmaceuticals (United States) (US)
- Johns Hopkins University (US)
- Duke Medical Center (US)
- Corresponding author
- Pajvani, Utpal B.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2018-11-21
- Volume
- 10
- Issue
- 468
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC6822168
- OpenAlex
- W2901663946
- Cited by
- 250
- References
- 78
- Citations by year
- 2026: 19 · 2025: 40 · 2024: 41 · 2023: 40 · 2022: 31 · 2021: 43 · 2020: 29 · 2019: 7
- FWCI
- 12.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK103818, DK105303)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- Notch signaling, hepatocytes, liver fibrosis, nonalcoholic steatohepatitis, antifibrotic therapy, diet-induced liver disease
- MeSH terms
- Animals, Choline, Diet, Female, Humans, Liver Cirrhosis, Male, Methionine, Mice, Inbred C57BL, Hepatocytes, Receptors, Notch, Osteopontin, Hepatic Stellate Cells, SOX9 Transcription Factor, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
